Clearmind (CMND) 13G/A: Capitalink reports ≤5% stake

Clearmind Medicine Inc. receiving a Schedule 13G/A amendment from Capitalink Ltd. reports ownership of 5 percent or less of the class of Common Shares (CUSIP 185053402).

Rhea-AI Filing Summary

Clearmind Medicine Inc. receiving a Schedule 13G/A amendment from Capitalink Ltd. reports ownership of 5 percent or less of the class of Common Shares (CUSIP 185053402).

The amendment (Amendment No. 3) lists Capitalink Ltd., an Israel entity, as the reporting person and incorporates cover-page items for detailed voting and dispositive power. The filing is signed by Lavi Krasney as CEO on 05/15/2026.

Insights

Corporate Governance Analyst

Filing documents a routine passive holding below the 5% reporting threshold.

The Schedule 13G/A amendment states Capitalink Ltd. holds "ownership of 5 percent or less of a class." This signals a non-control, passive reporting status under the applicable reporting regime.

Timing and detailed share counts are incorporated by reference to the cover pages; subsequent filings would show any material changes in ownership or dispositive power.

Compliance Counsel

Amendment formalizes disclosure and cites cover-page entries for voting and dispositive powers.

The form references items 5–11 on the cover pages for percent of class and voting/dispositive powers, preserving exact source wording. The signature block shows the filing was executed on 05/15/2026.

Because the filing records "Ownership of 5 percent or less," it aligns with passive investor reporting requirements rather than an active acquisition notice.

Key Figures

Ownership status: 5 percent or less CUSIP: 185053402 Amendment: Amendment No. 3 +2 more

5 metrics

Ownership status 5 percent or less Item 5: Ownership of 5 Percent or Less of a Class

CUSIP 185053402 Common Shares listed on the cover/Item 2(d)

Amendment Amendment No. 3 Filing header

Signature date 05/15/2026 Signed by Lavi Krasney/Chief Executive Officer

Reporting person citizenship Israel Item 2(c): Capitalink Ltd.

Key Terms

Schedule 13G/A, beneficially owned, dispositive power

3 terms

Schedule 13G/A regulatory

"Amendment No. 3 ) Clearmind Medicine Inc."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Amount beneficially owned: See items 5-11 of the cover pages hereto"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

dispositive power regulatory

"See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Capitalink Ltd.'s Schedule 13G/A for CMND report?

It reports ownership of 5 percent or less of Clearmind Medicine Inc. Common Shares. The amendment references cover-page items for voting and dispositive powers and is signed on 05/15/2026.

Does the filing show Capitalink has control over Clearmind (CMND)?

No. The filing states ownership of 5 percent or less, indicating a passive stake rather than control. The form refers to cover pages for detailed voting and dispositive power information.

Who signed the Schedule 13G/A amendment for CMND?

The amendment is signed by Lavi Krasney in the capacity of Chief Executive Officer. The signature block shows the execution date as 05/15/2026.

What security and identifier are listed in the filing for CMND?

The filing lists Common Shares, no par value per share and CUSIP 185053402. The title of class appears in Item 2(d) on the form.

Where is Capitalink Ltd. organized according to the filing?

The Schedule 13G/A states Capitalink Ltd.'s citizenship or place of organization as Israel and lists its address in Tel Aviv.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:15 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Clearmind Medicine Inc.

(Name of Issuer)

Common Shares, no par value per share

(Title of Class of Securities)

185053402

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 185053402

1

Names of Reporting Persons

Capitalink Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ISRAEL

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.00 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Clearmind Medicine Inc.
(b)	Address of issuer's principal executive offices: 101 - 1220 West 6th Avenue, Vancouver, BRITISH COLUMBIA, CANADA, V6H1A5.
Item 2.
(a)	Name of person filing: Capitalink Ltd.
(b)	Address or principal business office or, if none, residence: 20 Raoul Wallenberg Street, Tel Aviv, Israel 6971916
(c)	Citizenship: Israel
(d)	Title of class of securities: Common Shares, no par value per share
(e)	CUSIP No.: 185053402
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.
(b)	Percent of class: See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.
	(ii) Shared power to vote or to direct the vote: See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.
	(iii) Sole power to dispose or to direct the disposition of: See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.
	(iv) Shared power to dispose or to direct the disposition of: See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capitalink Ltd.

Signature:	/s/ Lavi Krasney
Name/Title:	Lavi Krasney/Chief Executive Officer
Date:	05/15/2026